Additionally, several animal studies demonstrate that TZDs also reduce urine albumin or protein excretion and protect against injury to the kidney [27]. Moreover, experimental studies exposed numerous actions of TZDs in the kidney that could explain a possible renoprotective effect [27-30]. Our recent study on diabetic rats showed that rosiglitazone exerts its anti-inflammatory renoprotective effect by inhibition of mesangial cells proliferation, downregulation of apoptosis and blunting responsiveness to angiotensin-2 [31].